CHICAGO--(BUSINESS WIRE)--Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately. PEB’s European licensee, Signature Diagnostics (SDX) completed the clinical trial and will present the results at the annual scientific meeting of the American Society of Clinical Oncology in Chicago on the 4th of June.
